DEXLANSOPRAZOLE (dexlansoprazole) by Viatris (2) is compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (h, k)-atpase at the secretory surface of the gastric parietal cell. Approved for symptomatic non-erosive gastroesophageal reflux disease (gerd), older for: • healing of all grades of erosive esophagitis (ee), older for healing of all grades of erosive esophagitis (ee) for up to eight weeks and 4 more indications. First approved in 2024.
Drug data last refreshed 20h ago
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H, K)-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been…
Worked on DEXLANSOPRAZOLE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation
A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules